Zacks Investment Research
27 Jul 2026, 16:30 UTC · 5w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Neurocrine Biosciences (NBIX) is scheduled to report second-quarter 2026 financial results on July 30 after market close. — Earnings reports typically trigger short-term volatility based on the delta between actual and consensus results.
+0.20The Zacks Consensus Estimate for NBIX second-quarter 2026 revenue is $901.54 million with earnings per share (EPS) of $2.26. — Provides the quantitative benchmark against which the market will judge the upcoming earnings performance.
+0.10Management has reaffirmed full-year sales guidance in the range of $2.7 billion to $2.8 billion. — Reaffirming guidance suggests stability and confidence in the current growth trajectory of flagship products.
+0.10Continue reading
6 related stories
Top 3 movers · tap to explore
Crenessity is acting as a new growth driver following its late 2024 FDA approval for classic congenital adrenal hyperplasia. — Positive fundamental development, though impact is gradual as it scales through physician adoption.
+0.05Which stocks this story touches
Positive outlook on flagship product Ingrezza and new growth driver Crenessity ahead of earnings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
